{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:26:24Z","timestamp":1792409184271,"version":"4.4.0"},"reference-count":6,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:p>This cross-sectional study examines the proportion of individuals with opioid use disorder (OUD) who initiated buprenorphine treatment without in-person visits under a temporary rule allowing tele-initiation of controlled substances.<\/jats:p>","DOI":"10.1001\/jamanetworkopen.2025.0001","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T16:03:10Z","timestamp":1741017790000},"page":"e250001","source":"Crossref","is-referenced-by-count":3,"title":["Tele-Buprenorphine Initiations for Opioid Use Disorder Without In-Person Relationships"],"prefix":"10.1001","volume":"8","author":[{"given":"Emma E.","family":"McGinty","sequence":"first","affiliation":[{"name":"Division of Health Policy and Economics, Weill Cornell Medical College and the Cornell Health Policy Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Ge","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Health Policy and Economics, Weill Cornell Medical College and the Cornell Health Policy Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla N.","family":"Tormohlen","sequence":"additional","affiliation":[{"name":"Division of Health Policy and Economics, Weill Cornell Medical College and the Cornell Health Policy Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Eisenberg","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"issue":"10","key":"zld250001r1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.3251","article-title":"Rebalancing Controlled Substance Regulations in Telemedicine.","volume":"4","author":"Kannarkat","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"1","key":"zld250001r2","doi-asserted-by":"publisher","DOI":"10.1093\/haschl\/qxad013","article-title":"Pandemic telehealth flexibilities for buprenorphine treatment: a synthesis of evidence and policy implications for expanding opioid use disorder care in the United States.","volume":"1","author":"Krawczyk","year":"2023","journal-title":"Health Aff Sch"},{"issue":"1","key":"zld250001r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.42531","article-title":"Use of telemedicine for buprenorphine inductions in patients with commercial insurance or Medicare Advantage.","volume":"5","author":"Barsky","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zld250001r6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11606-023-08383-1","article-title":"Telehealth initiation of buprenorphine for opioid use disorder: patient characteristics and outcomes.","volume":"39","author":"Nguyen","year":"2024","journal-title":"J Gen Intern Med"},{"key":"zld250001r4","unstructured":"Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications: A Rule by the Drug Enforcement Administration and the Health and Human Services Department on 11\/19\/2024. 21 CFR \u00a71307; 42 CFR \u00a712 (2024). Accessed December 17, 2024.  https:\/\/www.federalregister.gov\/documents\/2024\/11\/19\/2024-27018\/third-temporary-extension-of-covid-19-telemedicine-flexibilities-for-prescription-of-controlled"},{"key":"zld250001r5","unstructured":"The IQVIA Institute. Available IQVIA data. Accessed October 23, 2024. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/available-iqvia-data"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2830823\/mcginty_2025_ld_250001_1740068775.13264.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T16:03:14Z","timestamp":1741017794000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2830823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.0001","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]}}}